Prometrium for Menopause: Dosing, Evidence, and What to Expect

What Exactly Is Prometrium and How Does It Work in Menopause?

Prometrium is the brand name for oral micronized progesterone, a bioidentical hormone chemically identical to the progesterone the ovaries produced before menopause. When estrogen therapy is added back after menopause, it stimulates the uterine lining. Prometrium counters that stimulation by binding progesterone receptors in endometrial tissue, triggering secretory changes that prevent unchecked cell proliferation.

The word "micronized" refers to the manufacturing process. The progesterone molecule is ground into microscopic particles suspended in peanut oil, which dramatically improves intestinal absorption. Non-micronized oral progesterone is absorbed so poorly it produces negligible serum levels. Micronization raises peak serum concentration roughly fourfold compared to non-micronized preparations, making a 100 mg or 200 mg oral capsule clinically effective [1].

Progesterone also binds receptors outside the uterus. GABA-A receptors in the central nervous system respond to allopregnanolone, a neurosteroid metabolite of progesterone, which accounts for the sedative effect many patients notice. Binding at mineralocorticoid receptors produces mild natriuresis, which may partially explain why some women report less bloating on micronized progesterone compared to medroxyprogesterone acetate (MPA).

After oral administration, peak plasma concentrations appear at roughly 3 hours. The elimination half-life is approximately 25 to 50 hours with chronic dosing. Hepatic first-pass metabolism is substantial, so vaginal preparations of micronized progesterone (e.g., Prometrium used off-label vaginally or dedicated compounded formulations) produce lower systemic levels with higher local uterine concentrations, a distinction that matters when comparing systemic versus vaginal delivery routes [2].

Is Prometrium FDA-Approved for Menopause?

Yes, with a specific scope. The FDA approved Prometrium for two indications: (1) prevention of endometrial hyperplasia in postmenopausal women receiving daily conjugated estrogens 0.625 mg, and (2) treatment of secondary amenorrhea [3]. The first indication is the one relevant to menopause management.

That approval scope does not mean Prometrium is only pairable with conjugated estrogens at that specific dose. Clinicians routinely use it alongside other estrogen formulations (estradiol patches, gels, sprays, vaginal rings) at various doses. Those pairings represent standard off-label practice consistent with NAMS, ACOG, and AACE guidelines, all of which recognize micronized progesterone as an appropriate progestogen component across estrogen products [4].

The FDA label emphasizes that any woman with an intact uterus who takes systemic estrogen therapy requires a progestogen. Using estrogen alone in that population raises endometrial cancer risk. Prometrium satisfies that requirement. Women who have had a hysterectomy do not need a progestogen and should not add one without a specific clinical reason.

The PEPI Trial: The Core Clinical Evidence

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995, remains the most cited head-to-head comparison of progestogen types in postmenopausal women. Investigators randomized 875 healthy postmenopausal women to one of five arms over three years: placebo, conjugated equine estrogen (CEE) alone, CEE plus MPA continuously, CEE plus MPA cyclically, or CEE plus micronized progesterone cyclically [5].

Two findings from PEPI stand out for clinical practice.

First, endometrial protection. The CEE-alone arm produced endometrial hyperplasia in 62% of women with an intact uterus by year three, confirming that unopposed estrogen is genuinely hazardous. All three progestogen-containing arms reduced that risk to rates statistically comparable to placebo.

Second, lipid effects. The CEE-alone arm produced the largest HDL-cholesterol increase. Adding MPA (in either schedule) attenuated that benefit substantially. Micronized progesterone preserved significantly more of the estrogen-driven HDL rise than MPA did. Specifically, women on CEE plus cyclic micronized progesterone maintained HDL improvements that were not significantly different from the CEE-alone arm, while both MPA regimens showed meaningful HDL attenuation [5].

The PEPI investigators wrote: "Among women with a uterus, CEE with cyclic micronized progesterone was the optimal regimen for lipid benefit while protecting the endometrium" [5].

These findings set the foundation for viewing micronized progesterone as a metabolically preferable alternative to synthetic progestins, a position subsequent observational data and the E3N French cohort study have continued to support.

Prometrium Dosing for Menopause: Continuous vs. Cyclic Regimens

Dosing depends on whether a woman is using a continuous-combined or a sequential (cyclic) hormone therapy regimen.

Continuous-combined regimen. The patient takes estrogen every day and Prometrium 100 mg every night. This approach often produces irregular spotting in the first three to six months, after which most women become amenorrheic. It suits women who are at least twelve months past their last period and want to avoid any scheduled bleeding [6].

Sequential (cyclic) regimen. The patient takes estrogen every day and adds Prometrium 200 mg nightly for the first 12 days of each calendar month or each 28-day cycle. A scheduled withdrawal bleed typically occurs in the days after stopping Prometrium. This approach is sometimes preferred in early postmenopause or perimenopause because the bleeding pattern can help monitor uterine response and may feel more physiologically familiar [6].

Both regimens are listed in the FDA-approved labeling. The choice between them depends on time since menopause, patient preference regarding bleeding, body weight, and the specific estrogen preparation being used. Some clinicians increase the continuous dose to 200 mg nightly in heavier patients (>80 kg) or when breakthrough bleeding persists, though that titration is guided by clinical judgment rather than a published protocol.

The HealthRX clinical team uses a three-step decision framework when selecting between regimens. Step one: confirm menopause status and time since last period. Women who are fewer than 12 months postmenopausal or still perimenopausal generally start with the sequential regimen because irregular estrogen production makes continuous-combined therapy more likely to produce unpredictable bleeding. Step two: assess patient preference for scheduled versus no scheduled bleeding. Step three: review body weight and any prior progestogen tolerance history. A patient who experienced significant mood changes or bloating on MPA is a strong candidate for the 100 mg continuous schedule, starting at bedtime with food to reduce dizziness.

How Does Micronized Progesterone Compare to Medroxyprogesterone Acetate?

MPA (brand name Provera) was the dominant progestogen in U.S. hormone therapy for decades, partly because of its lower cost and oral bioavailability without micronization. The Women's Health Initiative (WHI) used CEE plus MPA in its combined-arm study and reported increased breast cancer risk after 5.6 years [7]. That finding alarmed patients and prescribers and contributed to a sharp drop in hormone therapy use nationally.

Observational data from the E3N cohort (N=80,377 French women followed over 8.1 years) reported that breast cancer risk associated with estrogen combined with micronized progesterone was not significantly elevated compared to never-users (relative risk 1.00 for estradiol plus progesterone in one analysis), while synthetic progestins including MPA showed elevated relative risks in the same dataset [8]. Observational data cannot establish causation the way a randomized trial can, and the WHI used a different estrogen (CEE) than E3N (mostly estradiol), so direct comparison requires caution.

What can be stated with more confidence: micronized progesterone does not antagonize estrogen's HDL benefit to the degree MPA does (PEPI), produces measurable sedation via neurosteroid pathways that many patients prefer to MPA's mood-blunting profile, and lacks the androgenic receptor activity MPA carries. For patients with sleep disruption as a prominent menopause symptom, the sedative property of micronized progesterone is a genuine clinical advantage rather than a side effect to manage.

Side Effects That Matter for Menopause Patients

Sedation. The allopregnanolone metabolite acts on GABA-A receptors, producing noticeable drowsiness within 1 to 2 hours of ingestion. Taking Prometrium at bedtime converts this from a nuisance into a therapeutic feature, particularly for women whose menopause includes insomnia. A 2011 crossover study (N=40) published in Menopause found that postmenopausal women on micronized progesterone 300 mg reported significantly better sleep quality, fewer waking episodes, and improved next-day alertness compared to baseline [9].

Dizziness on empty stomach. The peanut oil vehicle requires food for optimal and consistent absorption. Patients who take Prometrium on an empty stomach often report dizziness or a "floating" sensation within the first hour. Instructing patients to take it with a small snack virtually eliminates this complaint.

Breast tenderness. Any progestogen can cause breast tenderness, typically in the first two to three months. It usually resolves with continued use. Persistent breast changes should prompt clinical evaluation and mammogram review rather than immediate dose adjustment.

Mood effects. Some patients report mild depressive mood or anxiety fluctuations in the days after starting or increasing micronized progesterone. This is less common than with MPA but does occur. Women with a history of premenstrual dysphoric disorder (PMDD) may be particularly sensitive because the allopregnanolone pathway that produces sedation in most women produces paradoxical anxiety in a subset with GABA-A receptor variants. Switching to vaginal delivery or reducing frequency is an option in those cases [10].

Peanut allergy. The capsule contains peanut oil. This is not a theoretical concern. Women with documented peanut allergy should not use oral Prometrium. Compounded micronized progesterone capsules formulated in a non-peanut oil base are available as an alternative, though they lack FDA approval and require careful sourcing.

What is not a common side effect. Weight gain is frequently attributed to hormone therapy but is not consistently demonstrated in controlled trials of micronized progesterone specifically. Hot flash relief is produced by estrogen, not Prometrium. Patients sometimes expect Prometrium alone to reduce vasomotor symptoms; it does not, except modestly via central nervous system pathways that are not well-characterized in large trials.

Starting Prometrium: What the First 90 Days Look Like

Week one through two. Sedation is most pronounced during initiation. Most patients adapt within 7 to 14 days. Bedtime dosing handles this for most women without dose reduction.

Month one. Women on a continuous-combined regimen may notice light spotting or irregular bleeding as the endometrial lining adjusts. This is expected and not a reason to stop therapy unless the bleeding is heavy (heavier than a normal period) or prolonged beyond 10 days. Any heavy unscheduled bleeding in a postmenopausal woman warrants endometrial evaluation regardless of what therapy she is on.

Month two and three. Spotting usually diminishes on continuous therapy. Women on cyclic regimens will have a withdrawal bleed in the days after their 12-day Prometrium course ends. That bleed should be light and predictable. A bleed that is heavier than expected or occurs at the wrong time relative to the cycle structure should be evaluated.

Three months and beyond. At the three-month mark, most patients have stabilized. Serum progesterone levels are not routinely used to monitor oral Prometrium because absorption variability between lab draws is high. Endometrial surveillance with ultrasound or biopsy is indicated if abnormal bleeding occurs, not on a fixed screening schedule in asymptomatic patients [4].

Prometrium and Bone Health in Menopause

Estrogen is the dominant driver of bone preservation in hormone therapy. Prometrium's direct contribution to bone mineral density is secondary, though progesterone receptors do exist in osteoblasts and some in vitro data suggest progesterone may have an independent modest anabolic bone effect. The primary reason to add Prometrium to estrogen therapy in a woman with a uterus is endometrial protection, not bone benefit.

The 2023 Menopause Society position statement affirms that hormone therapy including estrogen plus progestogen reduces fracture risk in postmenopausal women, with the estrogen component doing the heavy lifting [4]. Women who start hormone therapy within 10 years of menopause or before age 60 show the most consistent bone preservation outcomes, a window often called the "timing hypothesis" or "window of opportunity."

Prometrium and Cardiovascular Considerations

The WHI data showed that the combined CEE plus MPA arm had a hazard ratio of 1.29 for coronary heart disease events compared to placebo [7]. Whether that excess risk was driven by MPA, by late initiation (average participant age was 63), or by CEE rather than estradiol has been actively debated. PEPI's lipid data suggest MPA specifically blunts cardioprotective HDL effects.

The Danish Osteoporosis Prevention Study (DOPS), which used estradiol plus norethindrone acetate rather than CEE plus MPA, reported a significantly lower risk of cardiovascular outcomes in the hormone therapy group when initiated close to menopause [11]. Micronized progesterone was not used in DOPS, but the direction of evidence from multiple sources suggests the progestogen type matters for cardiovascular outcomes in addition to the estrogen type and the timing of initiation.

No large randomized trial has enrolled sufficient numbers to isolate micronized progesterone's cardiovascular effect independently of the estrogen component. The E3N data and smaller mechanistic studies provide hypothesis-generating evidence that micronized progesterone is the preferable progestogen from a cardiovascular standpoint, but that conclusion carries appropriate uncertainty.

Monitoring and Follow-Up While on Prometrium

Routine monitoring for a woman on Prometrium as part of hormone therapy follows The Menopause Society and ACOG recommendations: annual clinical visit with blood pressure measurement, breast exam, and review of any bleeding patterns. No specific laboratory monitoring of progesterone levels is standard. Endometrial biopsy or transvaginal ultrasound is indicated for any unscheduled postmenopausal bleeding, not as routine surveillance [4].

Mammography should continue on the same schedule recommended for the patient's age. Women under 50 starting hormone therapy perimenopausal should follow USPSTF mammography screening guidance. Women 50 and older follow annual or biennial schedules per their risk profile and clinician guidance [12].

Bone density (DXA) at baseline and every one to two years in women with known low bone mass gives useful information about whether the estrogen component is working. Prometrium does not require separate monitoring beyond what estrogen therapy already prompts.

Insurance, Cost, and Access

Prometrium is available as a branded product and in generic forms (generic micronized progesterone 100 mg and 200 mg capsules became widely available after patent expiration). Generic versions cost significantly less. As of 2024, a 30-day supply of generic micronized progesterone 100 mg runs approximately $30 to $60 at major pharmacy chains with a GoodRx coupon, compared to $80 to $140 for branded Prometrium.

Insurance coverage varies. Most commercial plans cover generic micronized progesterone under Tier 1 or Tier 2, especially when prescribed alongside estrogen therapy. Medicare Part D plans typically cover it. Prior authorization is uncommon for the FDA-approved indication. Women paying out of pocket should request the generic by name from the pharmacist and compare prices across at least two pharmacy chains, as price variation at the pharmacy level is often larger than the formulary-tier difference.

Telehealth platforms, including HealthRX, can prescribe Prometrium in all states where licensed clinicians practice. Prescriptions are sent electronically to the patient's preferred pharmacy or mailed directly through affiliated specialty pharmacies.